Athira Pharma, Inc. (NASDAQ:LONA) Receives $16.00 Average PT from Analysts

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $16.00.

LONA has been the subject of a number of research reports. Citizens Jmp upgraded shares of Athira Pharma from a “market perform” rating to an “outperform” rating and set a $18.00 target price for the company in a research note on Thursday, July 30th. Piper Sandler began coverage on Athira Pharma in a report on Wednesday, May 27th. They issued an “overweight” rating and a $20.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research report on Friday, August 7th. Finally, Wall Street Zen raised Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th.

Athira Pharma Stock Up 0.1%

LONA opened at $7.98 on Monday. The firm has a 50 day moving average price of $8.26 and a 200-day moving average price of $8.24. Athira Pharma has a twelve month low of $3.52 and a twelve month high of $14.21. The stock has a market capitalization of $74.93 million, a price-to-earnings ratio of -1.53 and a beta of 2.05.

Athira Pharma (NASDAQ:LONA) last issued its earnings results on Friday, August 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.20). As a group, analysts expect that Athira Pharma will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On Athira Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Focus Partners Wealth bought a new position in shares of Athira Pharma in the third quarter worth approximately $35,000. Jane Street Group LLC bought a new stake in shares of Athira Pharma during the 4th quarter valued at $100,000. Renaissance Technologies LLC raised its position in shares of Athira Pharma by 44.7% during the 4th quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock valued at $569,000 after purchasing an additional 23,223 shares during the period. Seven Fleet Capital Management LP purchased a new position in shares of Athira Pharma during the 4th quarter valued at $969,000. Finally, Millennium Management LLC purchased a new position in shares of Athira Pharma during the 4th quarter valued at $2,456,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.